Acticor Biotech SAS (ALACT.PA)

4.99 €

-0.01 (-0.20%)
Rating:
Recommendation:
-
Symbol ALACT.PA
Price 4.99 €
Beta 0.000
Volume Avg. 0.00M
Market Cap 66.059M
Shares () -
52 Week Range 4.9-11.0
1y Target Est -
DCF Unlevered ALACT.PA DCF ->
DCF Levered ALACT.PA LDCF ->
ROE -379.15% Strong Sell
ROA -128.53% Strong Sell
Operating Margin -
Debt / Equity -350.56% Strong Sell
P/E -3.37 Strong Sell
P/B -23.46 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Dr. Gilles Avenard M.D.
Healthcare
Biotechnology
Paris

Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.